Lotte Kleinendorst

Lotte Kleinendorst

Auto-generated profile, based on publicly available information

Lotte Kleinendorst

Department of Human Genetics Amsterdam University Medical Center, University of Amsterdam Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
LKLotte Kleinendorst
Lotte Kleinendorst
MMMaarten P G Massink
Maarten P G Massink
MCMellody I Cooiman
Mellody I Cooiman
MSMesut Savas
Mesut Savas
OBOlga H van der Baan-Slootweg
Olga H van der Baan-Slootweg
MHMieke M van Haelst
Mieke M van Haelst
Background: Obesity is a global and severe health problem. Due to genetic heterogeneity, the identification of genetic defects in patients with obesity can be time consuming and costly. Therefore, we developed a custom diagnostic targeted next-generation sequencing (NGS)-based analysis to simultaneously identify mutations in 52 obesity-related genes. The aim of this study was to assess the diagnostic yield of this approach in patients with suspected genetic obesity. Methods: DNA of 1230 patients with obesity (median BMI adults 43.6 kg/m2; median body mass index-SD children +3.4 SD) was analysed in the genome diagnostics section of the Department of Genetics of the UMC Utrecht (The Netherlands) by targeted analysis of 52 obesity-related genes. Results: In 48 patients pathogenic mutations confirming the clinical diagnosis were detected. The majority of these were observed in the MC4R gene (18/48). In an additional 67 patients a probable pathogenic mutation was identified, necessitating further analysis to confirm the clinical relevance. Conclusions: NGS-based gene panel analysis in patients with obesity led to a definitive diagnosis of a genetic obesity disorder in 3.9% of obese probands, and a possible diagnosis in an additional 5.4% of obese probands. The highest yield was achieved in a selected paediatric subgroup, establishing a definitive diagnosis in 12 out of 164 children with severe early onset obesity (7.3%). These findings give a realistic insight in the diagnostic yield of genetic testing for patients with obesity and could help these patients to receive (future) personalised treatment.

11 April 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
NVNiels Vos
Niels Vos
LKLotte Kleinendorst
Lotte Kleinendorst
LLLiselot van der Laan
Liselot van der Laan
JUJorrit van Uhm
Jorrit van Uhm
PJPhilip R. Jansen
Philip R. Jansen
MVMieke Haelst, van
Mieke Haelst, van
The 16p11.2 deletion syndrome is a clinically heterogeneous disorder, characterized by developmental delay, intellectual disability, hyperphagia, obesity, macrocephaly and psychiatric problems. Cases with 16p11.2 duplication syndrome have similar neurodevelopmental problems, but typically show a partial ‘mirror phenotype’ with underweight and microcephaly. Various copy number variants (CNVs) of the chromosomal 16p11.2 region have been described. Most is known about the ‘typical’ 16p11.2 BP4-BP5 (29.6–30.2 Mb; ~600 kb) deletions and duplications, but there are also several published cohorts with more distal 16p11.2 BP2-BP3 CNVs (28.8–29.0 Mb; ~220 kb), who exhibit clinical overlap. We assessed 100 cases with various pathogenic 16p11.2 CNVs and compared their clinical characteristics to provide more clear genotype-phenotype correlations and raise awareness of the different 16p11.2 CNVs. Neurodevelopmental and weight issues were reported in the majority of cases. Cases with distal 16p11.2 BP2-BP3 deletion showed the most severe obesity phenotype (73.7% obesity, mean BMI SDS 3.2). In addition to the more well defined typical 16p11.2 BP4-BP5 and distal 16p11.2 BP2-BP3 CNVs, we describe the clinical features of five cases with other, overlapping, 16p11.2 CNVs in more detail. Interestingly, four cases had a second genetic diagnosis and 18 cases an additional gene variant of uncertain significance, that could potentially help explain the cases’ phenotypes. In conclusion, we provide an overview of our Dutch cohort of cases with various pathogenic 16p11.2 CNVs and relevant second genetic findings, that can aid in adequately recognizing, diagnosing and counseling of individuals with 16p11.2 CNVs, and describe the personalized medicine for cases with these conditions.

21 July 2021 in Clinical Obesity
Verified
Journal Article
Open access
MWMila S. Welling
Mila S. Welling
CGCornelis J. de Groot
Cornelis J. de Groot
LKLotte Kleinendorst
Lotte Kleinendorst
BVBibian Van der Voorn
Bibian Van der Voorn
JBJan Steven Burgerhart
Jan Steven Burgerhart
ERElisabeth F. C. van Rossum
Elisabeth F. C. van Rossum
Summary: Obesity is highly prevalent and comes with serious health burden. In a minority, a genetic cause is present which often results in therapy‐resistant obesity. Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue, which has beneficial effects on satiety and weight in common obesity. We present the effects of GLP‐1 analogues in adults with a molecularly proven genetic cause of their overweight or obesity. All patients were treated with liraglutide 3.0 mg daily, in addition to intensive supportive lifestyle treatment. Anthropometrics, metabolic parameters, resting energy expenditure (REE), side effects, and subjectively reported satiety and quality of life were assessed. Two patients with 16p11.2 deletion syndrome and two patients with heterozygous pathogenic melanocortin‐4 receptor variants were treated. At baseline, their age ranged between 21 and 32 years and body mass index (BMI) ranged between 28.1 and 55.7 kg/m2. At follow‐up (ranges 43 weeks–12 years), a mean change in BMI and waist circumference was observed of −5.7 ± 3.8 kg/m2 and −15.2 ± 21.1 cm, respectively. All patients achieved ≥5% weight loss, three of them lost ≥10% of their body weight. All patients reported improved quality of life and three of them reported ameliorated satiety. Moreover, improvement of glycaemic control and dyslipidaemia were seen. In two patients, REE before and during treatment was measured, which either increased (+26% of predicted REE) or decreased (−18% of predicted REE). Two patients experienced mild side effects for a brief period. In conclusion, our case series shows beneficial effects of GLP‐1 analogues on weight, metabolic parameters and quality of life in all four patients with genetic obesity.

25 September 2017 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
LKLotte Kleinendorst
Lotte Kleinendorst
MHMieke M van Haelst
Mieke M van Haelst
EAErica L T van Den Akker
Erica L T van Den Akker
This case report of an infant with severe early-onset obesity illustrates the societal condemnation of persons with obesity. In addition, it underlines the importance of diagnosing rare forms of monogenic obesity, even if no drug treatment is available. Here, we describe a 2-year-old girl with severe progressive obesity from birth onwards due to insatiable hunger. Genetic studies eventually reveal that the girl has a monogenic form of obesity caused by two mutations in the LEPR gene. No drug treatment is available (as yet) for this disease. Parents describe the stigmatic remarks they have to deal with every day. Diagnosing this rare genetic disorder was very important for understanding that satiety regulation is a complex system, of which willpower is only a small portion. In these patients, reduction of obesity can be achieved, but a different approach to lifestyle intervention is needed.

15 May 2020 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
LKLotte Kleinendorst
Lotte Kleinendorst
LHLieke M. van Den Heuvel
Lieke M. van Den Heuvel
LHLidewij Henneman
Lidewij Henneman
MHMieke M. van Haelst
Mieke M. van Haelst

20 September 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
LKLotte Kleinendorst
Lotte Kleinendorst
GCGraciela Pi Castán
Graciela Pi Castán
ACAlfonso Caro‐Llopis
Alfonso Caro‐Llopis
EBElles M. J. Boon
Elles M. J. Boon
MHMieke M. van Haelst
Mieke M. van Haelst